Kelun-Biotech Reports Phase III Success for sac-TMT in NSCLC
CHENGDU, China, July 14, 2026 Kelun-Biotech has announced a major clinical milestone after its Phase III OptiTROP-Lung06 trial evaluating...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
CHENGDU, China, July 14, 2026 Kelun-Biotech has announced a major clinical milestone after its Phase III OptiTROP-Lung06 trial evaluating...
Rahway, N.J., USA – May 18, 2026 Merck announced that its pivotal Phase 3 TroFuse-005 clinical trial evaluating sacituzumab...
